BREAKOUT SESSION 2
STRATEGY & DEVELOPMENT TRACK: Pain in the ChainGovernor E
The integrity of manufacturers’ supply chains has always been an important factor for the Bio/Med industry. A study of recent Warning Letters and Form 483s reveals that supply chain issues include among them, a lack of purchasing controls, inadequate inspections of incoming products and an absence of quality agreements between suppliers and OEMs that are frequently cited by the FDA. Aside from causing the industry regulatory problems, inadequate supply chain controls have also become a significant source of product liability for Bio/Med companies.
- What is the significance of the supply chain to the Bio/Med industry and how have lapses translated into long-term issues?
- What can companies do to ensure integrity of their supply chains and minimize the risks associated with their vendors and suppliers?
- How can improved supply chain visibility increase ROI and reduce disruption?
Brian Toglia - Moderator
Principal and Vice President, Tanner-Ibbotson, Inc.
Justin McCabe - Panelist
Senior Specialist, Business Development , Performance Review Institute
Courtney Stevens - Panelist
Senior Attorney , Medmarc
Kevin Webb - Panelist
Business Development Manager, Sparton
Michael Brousseau - Panelist
US Technical Lead, Medical, Intertek